CA2016962A1 - Conjugat polypeptide-anticorps pour inhiber l'adhesion des cellules - Google Patents
Conjugat polypeptide-anticorps pour inhiber l'adhesion des cellulesInfo
- Publication number
- CA2016962A1 CA2016962A1 CA002016962A CA2016962A CA2016962A1 CA 2016962 A1 CA2016962 A1 CA 2016962A1 CA 002016962 A CA002016962 A CA 002016962A CA 2016962 A CA2016962 A CA 2016962A CA 2016962 A1 CA2016962 A1 CA 2016962A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- polypeptide
- rgd
- molecule
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36261789A | 1989-05-17 | 1989-05-17 | |
US362,617 | 1989-05-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2016962A1 true CA2016962A1 (fr) | 1990-11-17 |
Family
ID=23426812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002016962A Abandoned CA2016962A1 (fr) | 1989-05-17 | 1990-05-16 | Conjugat polypeptide-anticorps pour inhiber l'adhesion des cellules |
Country Status (6)
Country | Link |
---|---|
AU (1) | AU5815990A (fr) |
CA (1) | CA2016962A1 (fr) |
GR (1) | GR900100372A (fr) |
IE (1) | IE901736L (fr) |
PT (1) | PT94067A (fr) |
WO (1) | WO1990014103A1 (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6406697B1 (en) | 1989-02-23 | 2002-06-18 | Genentech, Inc. | Hybrid immunoglobulins |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5612311A (en) | 1990-04-06 | 1997-03-18 | La Jolla Cancer Research Foundation | Method and composition for treating thrombosis |
US6521594B1 (en) | 1990-04-06 | 2003-02-18 | La Jolla Cancer Research Foundation | Method and composition for treating thrombosis |
US5780303A (en) * | 1990-04-06 | 1998-07-14 | La Jolla Cancer Research Foundation | Method and composition for treating thrombosis |
JP3283041B2 (ja) * | 1990-07-13 | 2002-05-20 | 学校法人藤田学園 | 人工抗体 |
ATE175122T1 (de) * | 1991-05-03 | 1999-01-15 | Univ Rockefeller | Endothelzell-ligand für den leukocyten cr3 erkennender antikörper |
ZA937553B (en) * | 1992-10-12 | 1994-05-03 | Agen Ltd | Clot directed anticoagulant process for making same and methods of use |
US6180134B1 (en) | 1993-03-23 | 2001-01-30 | Sequus Pharmaceuticals, Inc. | Enhanced ciruclation effector composition and method |
US5753230A (en) * | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
CA2301799C (fr) * | 1997-11-07 | 2007-08-07 | Conjuchem, Inc. | Nouveaux conjugues opioides et supports endogenes |
CN1399554A (zh) * | 1999-09-23 | 2003-02-26 | 斯克里普斯研究学院 | 抑制粘连形成的方法和组合物 |
PT1272507E (pt) | 2000-04-12 | 2005-11-30 | Amersham Health As | Derivados de peptidos para ligacao a integrina |
NO20004795D0 (no) | 2000-09-26 | 2000-09-26 | Nycomed Imaging As | Peptidbaserte forbindelser |
MXPA04000173A (es) | 2001-07-10 | 2004-03-18 | Amersham Health As | Compuestos basados en peptidos. |
US20110256055A1 (en) | 2008-12-23 | 2011-10-20 | Ge Healthcare Limited | Application of 99mtc peptide-based compound as a bone marrow imaging agent |
WO2011112549A2 (fr) * | 2010-03-10 | 2011-09-15 | Emory University | Compositions conjuguées sensibles à la température, et applications correspondantes |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
CA1203164A (fr) * | 1982-03-09 | 1986-04-15 | Thomas J. Mckearn | Conjugats d'anticorps |
EP0108146B1 (fr) * | 1982-05-12 | 1987-01-28 | The President And Fellows Of Harvard College | Gènes de fusion codant des protéines hybrides, vecteurs de clonage les contenant et leur emploi |
-
1990
- 1990-05-14 IE IE901736A patent/IE901736L/xx unknown
- 1990-05-15 AU AU58159/90A patent/AU5815990A/en not_active Abandoned
- 1990-05-15 WO PCT/US1990/002746 patent/WO1990014103A1/fr unknown
- 1990-05-16 GR GR900100372A patent/GR900100372A/el unknown
- 1990-05-16 CA CA002016962A patent/CA2016962A1/fr not_active Abandoned
- 1990-05-16 PT PT94067A patent/PT94067A/pt not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU5815990A (en) | 1990-12-18 |
PT94067A (pt) | 1991-02-08 |
IE901736L (en) | 1990-11-17 |
GR900100372A (el) | 1991-10-10 |
WO1990014103A1 (fr) | 1990-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2016962A1 (fr) | Conjugat polypeptide-anticorps pour inhiber l'adhesion des cellules | |
US5284751A (en) | Antibodies that bind to a ligand-induced binding site on GPIIIa | |
US7696324B2 (en) | Humanized antibodies | |
FI100184B (fi) | Ihmisen kudostekijään liittyvä DNA-kappale ja yhdistelmä-DNA-molekyyli sekä menetelmä proteiinin valmistamiseksi | |
US5149780A (en) | Peptides and antibodies that inhibit integrin-ligand binding | |
EP0619839B1 (fr) | Nouveaux polypeptides promoteurs de la fixation de cellules | |
US5204445A (en) | Peptides and antibodies that inhibit integrin-ligand binding | |
US5196511A (en) | Peptides and antibodies that inhibit integrin-ligand binding | |
US5262520A (en) | Peptides and antibodies that inhibit integrin-ligand binding | |
JP3455743B2 (ja) | ヒトpdgfベータ・レセプタに対する阻害性免疫グロブリン・ポリペプチド | |
IE913959A1 (en) | Antibodies that bind to a ligand-induced binding site on¹integrin and induce integrin activation | |
AU5007901A (en) | Antibodies against SEMP1, methods for their production and uses thereof | |
WO1989005155A1 (fr) | Anticorps monoclonal utilise contre le recepteur d'adhesion a direction rgd de cellules endotheliales | |
WO1996008513A1 (fr) | Derives de cytotactine stimulant la connexion neuronale et la croissance des axones et des dendrites, leurs procedes de preparation et d'utilisation | |
CA2095404A1 (fr) | Purification et caracterisation d'un recepteur d'adhesion specifique de la region csvtcg d'une cellule tumorale | |
CN114340671A (zh) | 对gpc3特异性的抗体及其使用方法 | |
WO1994014848A1 (fr) | Immunoglobulines produites par genie genetique | |
WO1992007872A1 (fr) | Peptides apparentes a la tenascine | |
CA2068813A1 (fr) | Anticorps monoclonaux hybrides et compositions les renfermant | |
IE20040562A1 (en) | Human tissue factor related DNA segments, polypeptides and antibodies. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |